

Client: ARUP Example Report Only  
500 Chipeta Way  
Salt Lake City, UT 84108  
UNITED STATES

Physician: arup, arup

**Patient: SKEL FE, NEGATIVE EXAMPLE**

**DOB**

**Sex:** Female

**Patient Identifiers:** 41278

**Visit Number (FIN):** 41602

**Collection Date:** 8/15/2022 11:31

**Skeletal Dysplasia Panel, Sequencing and Deletion/Duplication, Fetal**

ARUP test code 2012010

Maternal Contamination Study Fetal Spec

Fetal Cells

Single fetal genotype present; no maternal cells present. Fetal and maternal samples were tested using STR markers to rule out maternal cell contamination.

Maternal Contam Study, Maternal Spec

Whole Blood

For quality assurance purposes, ARUP Laboratories will confirm the above result at no charge following delivery. Order Confirmation of Fetal Testing and include a copy of the original fetal report (or the mother's name and date of birth) with the test submission. Please contact an ARUP genetic counselor at (800) 242-2787 extension 2141 prior to specimen submission.

Skeletal Dysplasia Panel Specimen, Fetal

Cultured Amnio

Skeletal Dysplasia Panel Interp, Fetal

Negative

INDICATION FOR TESTING

Suspected skeletal dysplasia

RESULT

No pathogenic variants were detected in any of the genes tested.

INTERPRETATION

No pathogenic variants were identified by massively parallel sequencing of the coding regions and exon-intron boundaries of the genes tested. No large exonic deletions and duplications were identified in the genes tested. This result decreases, but does not exclude, a diagnosis of a skeletal dysplasia. Please refer to the background information included in this report for a list of the genes analyzed and limitations of this test.

RECOMMENDATIONS

Medical screening and management should rely on clinical findings and family history. Genetic consultation is recommended.

COMMENTS

Likely benign and benign variants are not reported.

Variants in the following regions may not be detected by NGS with sufficient confidence in this sample due to technical limitations; reportable variants are confirmed by Sanger sequencing: NONE

This result has been reviewed and approved by Rong Mao, M.D.

BACKGROUND INFORMATION: Skeletal Dysplasia Panel, Sequencing and Deletion/Duplication, Fetal

CHARACTERISTICS: skeletal dysplasias are a heterogeneous group of more than 400 disorders characterized by abnormal growth of cartilage or bone. Clinical features may include shortening,

**H=High, L=Low, \*=Abnormal, C=Critical**

Unless otherwise indicated, testing performed at:

ARUP LABORATORIES | 800-522-2787 | aruplab.com  
500 Chipeta Way, Salt Lake City, UT 84108-1221  
Jonathan R. Genzen, MD, PhD, Laboratory Director

Patient: SKEL FE, NEGATIVE EXAMPLE

ARUP Accession: 22-227-106171

Patient Identifiers: 41278

Visit Number (FIN): 41602

Page 1 of 3 | Printed: 8/15/2022 11:40:12 AM

bowing, fracturing, thinning, thickening, or under mineralization of the bones; abnormal ribs; small chest circumference; and extra fingers or toes. Some disorders may be detectable prenatally while others are not identified until birth or later childhood.

**EPIDEMIOLOGY:** Collective incidence of 1 in 5000

**CAUSE:** Pathogenic germline variants in genes associated with cartilage and bone growth.

**INHERITANCE:** Contingent on etiology; autosomal recessive, autosomal dominant, and X-linked inheritance, depending on the causative gene

**CLINICAL SENSITIVITY:** Dependent on the specific skeletal dysplasia; 99 percent for achondroplasia and thanatophoric dysplasia; greater than 95 percent for COL1A1/2 osteogenesis imperfecta; greater than 90 percent for achondrogenesis type 1B, diastrophic dysplasia, and campomelic dysplasia.

**GENES TESTED:** AGPS, ALPL, ARSL, CANT1, CCN6, CILK1, COL1A1, COL1A2, \* COL2A1, COL10A1, COL11A1, COL11A2, COMP, CRTAP, DDR2, DLL3, DYM, \* DYNC2H1, EBP, EVC, \* EVC2, FGFR1, \* FGFR2, FGFR3, FKBP10, FLNA, FLNB, GDF5, GNPAT, HSPG2, IFT80, INPPL1, LBR, LIFR, NEK1, \* NPR2, P3H1, PCNT, PEX7, POR, \* PPIB, PTH1R, RUNX2, SERPINH1, SLC26A2, SLC35D1, SMARCAL1, SOX9, TRIP11, TRPV4, TTC21B, WDR19, WDR35

\*One or more exons are not covered by sequencing and/or deletion/duplication analysis for the indicated gene; see limitations section below.

**METHODOLOGY:** Probe hybridization-based capture of all coding exons and exon-intron junctions of the targeted genes, followed by massively parallel sequencing. Sanger sequencing was performed as necessary to fill in regions of low coverage and to confirm reported variants that do not meet acceptable quality metrics. A proprietary bioinformatic algorithm was used to detect large (single exon-level or larger) deletions or duplications in the indicated genes. Large deletions/duplications confirmed using an orthogonal exon-level microarray. Human genome build 19 (Hg 19) was used for data analysis.

**ANALYTICAL SENSITIVITY:** The analytical sensitivity is approximately 99 percent for single nucleotide variants (SNVs) and greater than 93 percent for insertions/duplications/deletions (indels) from 1-10 base pairs in size. Indels greater than 10 base pairs may be detected, but the analytical sensitivity may be reduced. Deletions of 2 exons or larger are detected with sensitivity greater than 97 percent; single exon deletions are detected with 62 percent sensitivity. Duplications of 3 exons or larger are detected at greater than 83 percent sensitivity. Specificity is greater than 99.9 percent for all variant classes.

**LIMITATIONS:** A negative result does not exclude diagnosis of a skeletal dysplasia. This test only detects variants within the coding regions and intron-exon boundaries of the targeted genes. Variants in the chr17:70,119,704-70,119,743 region of SOX9 exon 3 may not be detected. Deletions/duplications/insertions of any size may not be detected by massively parallel sequencing. Regulatory region variants and deep intronic variants will not be identified, including deletions/duplications in the upstream regulatory region of SOX9. Precise breakpoints for large deletions or duplications are not determined in this assay and single exon deletions/duplications may not be detected based on the breakpoints of the rearrangement. The actual breakpoints for the deletion or duplication may extend beyond or be within the exon(s) reported. This test is not intended to detect

---

**H=High, L=Low, \*=Abnormal, C=Critical**

---

Unless otherwise indicated, testing performed at:

**ARUP LABORATORIES | 800-522-2787 | aruplab.com**  
500 Chipeta Way, Salt Lake City, UT 84108-1221  
Jonathan R. Genzen, MD, PhD, Laboratory Director

Patient: SKEL FE, NEGATIVE EXAMPLE  
ARUP Accession: 22-227-106171  
Patient Identifiers: 41278  
Visit Number (FIN): 41602  
Page 2 of 3 | Printed: 8/15/2022 11:40:12 AM

duplications of 2 or fewer exons in size, though these may be identified. Single exon deletions are reported but called at a lower sensitivity. Diagnostic errors can occur due to rare sequence variations. In some cases, variants may not be identified due to technical limitations caused by the presence of pseudogenes, repetitive, or homologous regions. This test is not intended to detect low-level mosaic or somatic variants, gene conversion events, complex inversions, translocations, mitochondrial DNA (mtDNA) mutations, or repeat expansions. Interpretation of this test result may be impacted if this patient has had an allogeneic stem cell transplantation. Noncoding transcripts were not analyzed.

The following regions are not sequenced due to technical limitations of the assay:  
EVC(NM\_153717) exon(s) 1

Single exon deletions/duplications will not be called for the following exons:  
COL1A2(NM\_000089) 3; EVC (NM\_153717) 1; EVC(NM\_001306090) 1; EVC(NM\_001306092) 1; FGFR1(NM\_001354367) 18; FGFR1(NM\_001354369) 18; FGFR1(NM\_001354370) 17; DYM(NM\_001353212) 14; DYM(NM\_001353213) 14; DYM(NM\_001353214) 14; DYM(NM\_001353215) 14; DYM(NM\_001374428) 15; DYM(NM\_001374429) 14; DYM(NM\_001374430) 14 18; DYM(NM\_001374431) 14; DYM(NM\_001374432) 13; DYM(NM\_001374433) 17; DYM(NM\_001374441) 9; NEK1(NM\_001374422) 17; NEK1(NM\_001374423) 16; POR (NM\_001382655) 3

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

Counseling and informed consent are recommended for genetic testing. Consent forms are available online.

VERIFIED/REPORTED DATES

Procedure	Accession	Collected	Received	Verified/Reported
Maternal Contamination Study Fetal Spec	22-227-106171	8/15/2022 11:31:00 AM	8/15/2022 11:31:22 AM	8/15/2022 11:39:00 AM
Maternal Contam Study, Maternal Spec	22-227-106171	8/15/2022 11:31:00 AM	8/15/2022 11:31:22 AM	8/15/2022 11:39:00 AM
Skeletal Dysplasia Panel Specimen, Fetal	22-227-106171	8/15/2022 11:31:00 AM	8/15/2022 11:31:22 AM	8/15/2022 11:39:00 AM
Skeletal Dysplasia Panel Interp, Fetal	22-227-106171	8/15/2022 11:31:00 AM	8/15/2022 11:31:22 AM	8/15/2022 11:39:00 AM

END OF CHART

**H=High, L=Low, \*=Abnormal, C=Critical**

Unless otherwise indicated, testing performed at:

**ARUP LABORATORIES | 800-522-2787 | aruplab.com**  
500 Chipeta Way, Salt Lake City, UT 84108-1221  
Jonathan R. Genzen, MD, PhD, Laboratory Director

Patient: SKEL FE, NEGATIVE EXAMPLE  
ARUP Accession: 22-227-106171  
Patient Identifiers: 41278  
Visit Number (FIN): 41602  
Page 3 of 3 | Printed: 8/15/2022 11:40:12 AM